First Houston Capital Upped Hologic (HOLX) Holding By $414,000; Senzar Asset Management Lowered Its Tg Therapeutics (TGTX) Position

November 14, 2017 - By Peter Erickson

First Houston Capital Inc increased Hologic Inc (HOLX) stake by 40.35% reported in 2017Q2 SEC filing. First Houston Capital Inc acquired 9,200 shares as Hologic Inc (HOLX)’s stock rose 7.50%. The First Houston Capital Inc holds 32,000 shares with $1.45M value, up from 22,800 last quarter. Hologic Inc now has $11.11B valuation. The stock declined 0.03% or $0.01 reaching $39.61 on the news. About 4.08M shares traded or 29.94% up from the average. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since November 14, 2016 and is uptrending. It has outperformed by 12.51% the S&P500.

Senzar Asset Management Llc decreased Tg Therapeutics Inc (TGTX) stake by 14.97% reported in 2017Q2 SEC filing. Senzar Asset Management Llc sold 170,600 shares as Tg Therapeutics Inc (TGTX)’s stock rose 144.09%. The Senzar Asset Management Llc holds 969,300 shares with $9.74M value, down from 1.14 million last quarter. Tg Therapeutics Inc now has $611.14 million valuation. The stock declined 0.40% or $0.03 reaching $8.62 per share. About 1.54M shares traded or 7.69% up from the average. TG Therapeutics Inc (NASDAQ:TGTX) has risen 60.54% since November 14, 2016 and is uptrending. It has outperformed by 43.84% the S&P500.

First Houston Capital Inc decreased Dow Chem Co (NYSE:DOW) stake by 4,950 shares to 50,000 valued at $3.15 million in 2017Q2. It also reduced Valero Energy Corp New (NYSE:VLO) stake by 7,354 shares and now owns 27,600 shares. Allstate Corp (NYSE:ALL) was reduced too.

Among 17 analysts covering Hologic (NASDAQ:HOLX), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. Hologic had 40 analyst reports since July 24, 2015 according to SRatingsIntel. Needham maintained Hologic, Inc. (NASDAQ:HOLX) rating on Friday, June 2. Needham has “Buy” rating and $5000 target. The company was downgraded on Wednesday, February 15 by Bank of America. The rating was downgraded by Needham to “Hold” on Thursday, April 28. The company was upgraded on Friday, September 23 by Barclays Capital. The firm has “Equal Weight” rating given on Wednesday, September 2 by Barclays Capital. The stock has “Hold” rating by RBC Capital Markets on Friday, September 22. The rating was maintained by RBC Capital Markets with “Hold” on Friday, August 11. Canaccord Genuity maintained the shares of HOLX in report on Thursday, June 15 with “Buy” rating. Deutsche Bank maintained Hologic, Inc. (NASDAQ:HOLX) rating on Thursday, August 3. Deutsche Bank has “Buy” rating and $49 target. Stifel Nicolaus upgraded the shares of HOLX in report on Friday, December 11 to “Buy” rating.

Since May 17, 2017, it had 0 insider purchases, and 5 selling transactions for $1.75 million activity. $395,720 worth of stock was sold by Levy Lawrence M on Wednesday, May 31. Valenti Peter J. III also sold $434,635 worth of Hologic, Inc. (NASDAQ:HOLX) shares. $393,183 worth of Hologic, Inc. (NASDAQ:HOLX) was sold by ULLIAN ELAINE.

Investors sentiment increased to 1.38 in Q2 2017. Its up 0.28, from 1.1 in 2017Q1. It is positive, as 41 investors sold HOLX shares while 136 reduced holdings. 66 funds opened positions while 179 raised stakes. 267.53 million shares or 3.16% more from 259.34 million shares in 2017Q1 were reported. Ubs Asset Mgmt Americas Inc owns 942,606 shares for 0% of their portfolio. Caprock Group invested in 0.05% or 4,725 shares. Oppenheimer Asset Mgmt, a New York-based fund reported 15,187 shares. Meeder Asset Mgmt holds 0.01% or 1,262 shares. Wedge Capital Mngmt L LP Nc owns 874,039 shares for 0.38% of their portfolio. Bokf Na stated it has 130,004 shares or 0.19% of all its holdings. Capstone Asset Mgmt has 33,662 shares for 0.04% of their portfolio. Kentucky Retirement holds 17,950 shares or 0.06% of its portfolio. Calamos Advsrs Ltd Liability Co has 349,745 shares. Walleye Trading Limited Com reported 0% in Hologic, Inc. (NASDAQ:HOLX). Exxonmobil Inv Mgmt Tx holds 0.06% or 53,762 shares. Paradigm Asset Ltd Liability Com invested in 0% or 550 shares. Los Angeles Capital And Equity Rech has invested 0% in Hologic, Inc. (NASDAQ:HOLX). Eastern National Bank & Trust has invested 0.65% in Hologic, Inc. (NASDAQ:HOLX). D E Shaw And Co holds 0.06% or 820,625 shares in its portfolio.

Among 7 analysts covering TG Therapeutics (NASDAQ:TGTX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 11 analyst reports since August 12, 2015 according to SRatingsIntel. As per Tuesday, March 7, the company rating was maintained by H.C. Wainwright. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Hold” rating by Zacks on Wednesday, August 12. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by H.C. Wainwright on Wednesday, August 12. Raymond James initiated the stock with “Strong Buy” rating in Wednesday, September 9 report. The firm has “Buy” rating given on Friday, May 27 by Suntrust Robinson. Brean Capital reinitiated TG Therapeutics Inc (NASDAQ:TGTX) on Thursday, October 6 with “Buy” rating. The stock has “Outperform” rating by FBR Capital on Tuesday, December 1. The rating was initiated by SunTrust with “Buy” on Friday, May 27. Jefferies maintained TG Therapeutics Inc (NASDAQ:TGTX) on Monday, June 5 with “Buy” rating. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Buy” rating given on Thursday, June 15 by FBR Capital.

Since June 16, 2017, it had 0 buys, and 1 sale for $665,133 activity. Shares for $665,133 were sold by Power Sean A on Friday, June 16.

Senzar Asset Management Llc increased Forward Pharma A/S stake by 180,200 shares to 652,500 valued at $13.27M in 2017Q2. It also upped Alder Biopharmaceuticals Inc (NASDAQ:ALDR) stake by 342,700 shares and now owns 557,770 shares. Neuroderm Ltd was raised too.

Investors sentiment increased to 2.28 in Q2 2017. Its up 0.25, from 2.03 in 2017Q1. It is positive, as 6 investors sold TGTX shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 33.91 million shares or 12.20% more from 30.22 million shares in 2017Q1 were reported. Bessemer Grp has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX). Dupont Capital Management Corporation reported 25,662 shares. Metropolitan Life Insurance holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 30,247 shares. New York State Common Retirement Fund accumulated 0% or 102,853 shares. University Of Notre Dame Du Lac reported 0.63% in TG Therapeutics Inc (NASDAQ:TGTX). Segall Bryant & Hamill Limited Liability stated it has 53,592 shares. Kennedy Capital Mgmt owns 565,178 shares or 0.11% of their US portfolio. Credit Suisse Ag holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 200,552 shares. Barclays Public Limited, United Kingdom-based fund reported 54,077 shares. Swiss Natl Bank owns 79,200 shares for 0% of their portfolio. Tiaa Cref Inv Mngmt Ltd Liability Company holds 165,741 shares or 0% of its portfolio. Hanson Mcclain holds 0% in TG Therapeutics Inc (NASDAQ:TGTX) or 62 shares. Legal General Group Inc Public Ltd Com holds 11,264 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has 2,255 shares. Bb&T Secs Limited Liability owns 16,949 shares.

Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on March, 9. They expect $-0.47 earnings per share, up 2.08% or $0.01 from last year’s $-0.48 per share. After $-0.48 actual earnings per share reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.08% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com